H 003 - Halda Therapeutics
Alternative Names: H-003 - Halda TherapeuticsLatest Information Update: 29 Jun 2023
At a glance
- Originator Halda Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 26 Apr 2023 Halda Therapeutics plans a IND-enabling studies for Prostate cancer in 2023
- 17 Apr 2023 Preclinical trials in Prostate cancer in USA (PO) (before April 2023)
- 17 Apr 2023 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the American Association for Cancer Research (AACR-2023)